Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.

ABSTRACT:

Purpose

Ramucirumab was shown to be effective as a second-line treatment after sorafenib in patients with advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein levels > 400 ng/mL in a worldwide phase 3 trial. Ramucirumab is used in patients pretreated with various systemic therapies in clinical practice. We retrospectively examined the treatment outcomes of ramucirumab administered to advanced HCC patients after diverse systemic therapies.

Methods

Data were collected from patients with advanced HCC who received ramucirumab at three institutions in Japan. Radiological assessments were determined according to both Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and modified RECIST and the Common Terminology Criteria for Adverse Events version 5.0 wa

SUBMITTER: Kanogawa N 

PROVIDER: S-EPMC10007811 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature